BerGenBio ASA – LSE:0RU5.L
BerGenBio ASA stock price today
BerGenBio ASA stock price monthly change
BerGenBio ASA stock price quarterly change
BerGenBio ASA stock price yearly change
BerGenBio ASA key metrics
Market Cap | 333.02M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.51 |
Revenue | N/A |
EBITDA | -161.06M |
Income | -154.52M |
Revenue Q/Q | N/A |
Revenue Y/Y | 33.93% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeBerGenBio ASA stock price history
BerGenBio ASA stock forecast
BerGenBio ASA financial statements
| Jun 2023 | 0 | -48.83M | |
|---|---|---|---|
| Sep 2023 | 0 | -27.93M | |
| Dec 2023 | 354K | -41.63M | -11761.58% |
| Mar 2024 | 167K | -36.11M | -21626.95% |
| 2025 | 169.51K | -88.45M | -52180.58% |
|---|---|---|---|
| 2026 | 117.30K | -99.97M | -85227.75% |
| 2027 | 81.17K | -108.20M | -133301.79% |
| 2028 | 18.7M | -120.65M | -645.23% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 240446000 | 52.40M | 21.8% |
|---|---|---|---|
| Sep 2023 | 187997000 | 26.83M | 14.27% |
| Dec 2023 | 174335000 | 46.85M | 26.88% |
| Mar 2024 | 135433000 | 42.11M | 31.1% |
| Jun 2023 | -63.29M | 70K | 217.40M |
|---|---|---|---|
| Sep 2023 | -55.34M | 0 | -96K |
| Dec 2023 | -22.10M | 2.69M | 7.57M |
| Mar 2024 | -42.59M | 167K | -102K |
BerGenBio ASA alternative data
| Aug 2023 | 28 |
|---|---|
| Sep 2023 | 28 |
| Oct 2023 | 28 |
| Nov 2023 | 28 |
| Dec 2023 | 18 |
| Jan 2024 | 18 |
| Feb 2024 | 18 |
| Mar 2024 | 18 |
| Apr 2024 | 18 |
| May 2024 | 18 |
| Jun 2024 | 16 |
| Jul 2024 | 15 |
BerGenBio ASA other data
| Insider | Compensation |
|---|---|
Mr. Richard Godfrey Chief Executive Officer | $4,230,000 |
Prof. Hani Gabra Chief Medical Officer | $1,810,000 |
Prof. James B. Lorens Co-Founder & Chief Scientific Officer | $1,790,000 |
Dr. James Barnes Ph.D. Director of Operations | $1,780,000 |
Mr. Rune Skeie (1974) Chief Financial Officer | $1,670,000 |
Ms. Debbie Molyneux Interim HR Director |
-
What's the price of BerGenBio ASA stock today?
One share of BerGenBio ASA stock can currently be purchased for approximately $20.3.
-
When is BerGenBio ASA's next earnings date?
Unfortunately, BerGenBio ASA's (0RU5.L) next earnings date is currently unknown.
-
Does BerGenBio ASA pay dividends?
No, BerGenBio ASA does not pay dividends.
-
How much money does BerGenBio ASA make?
BerGenBio ASA has a market capitalization of 333.02M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 9% to 354K US dollars.
-
What is BerGenBio ASA's stock symbol?
BerGenBio ASA is traded on the LSE under the ticker symbol "0RU5.L".
-
What is BerGenBio ASA's primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of BerGenBio ASA?
Shares of BerGenBio ASA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are BerGenBio ASA's key executives?
BerGenBio ASA's management team includes the following people:
- Mr. Richard Godfrey Chief Executive Officer()
- Prof. Hani Gabra Chief Medical Officer()
- Prof. James B. Lorens Co-Founder & Chief Scientific Officer()
- Dr. James Barnes Ph.D. Director of Operations()
- Mr. Rune Skeie Chief Financial Officer(age: 51, pay: $1,670,000)
- Ms. Debbie Molyneux Interim HR Director
-
Is BerGenBio ASA founder-led company?
Yes, BerGenBio ASA is a company led by its founder Prof. James B. Lorens.
-
How many employees does BerGenBio ASA have?
As Jul 2024, BerGenBio ASA employs 15 workers, which is 6% less then previous month and 17% less then previous quarter.
-
When BerGenBio ASA went public?
BerGenBio ASA is publicly traded company for more then 7 years since IPO on 13 Dec 2017.
-
What is BerGenBio ASA's official website?
The official website for BerGenBio ASA is bergenbio.com.
-
How can i contact BerGenBio ASA?
BerGenBio ASA can be reached via phone at +47 55 96 11 59.
BerGenBio ASA company profile:
BerGenBio ASA
bergenbio.comLSE
15
Medical - Pharmaceuticals
Healthcare
BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in development of drugs to treat immune evasive, drug resistant, and metastatic cancers; and respiratory diseases. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. Its Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase Ib clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is based in Bergen, Norway.
Bergen, 5009
:
ISIN: NO0010650013
CUSIP: R08326101
